Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.5385
+0.00230.43%
Volume:316.57K
Turnover:170.67K
Market Cap:127.95M
PE:-1.43
High:0.5440
Open:0.5354
Low:0.5337
Close:0.5362
Loading ...

Sangamo Therapeutics Delays Q1 2025 Earnings Call to Later Time on May 12

Reuters
·
13 May

Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
10 May

Press Release: Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Dow Jones
·
07 May

Sangamo Therapeutics: St-920 Study Pivotal Data Readout Expected by End of Q2 2025

THOMSON REUTERS
·
06 May

Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
05 May

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Business Wire
·
29 Apr

US Stocks Likely To Open Lower After The Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert

Benzinga
·
04 Apr

Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday

Benzinga
·
04 Apr

Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics

Dow Jones
·
04 Apr

BRIEF-Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System

Reuters
·
04 Apr

Shares of Sangamo Therapeutics Rally on Licensing Deal With Eli Lilly

Dow Jones
·
04 Apr

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours

MT Newswires Live
·
04 Apr

Sangamo Therapeutics Enters Capsid License Agreement With Lilly

Dow Jones
·
04 Apr

Sangamo: Agreement Grants Lilly Rights to Employ Co's Novel Proprietary Capsid, Stac-Bbb, for up to 5 Potential Disease Targets

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Inc: Eligible to Earn up to $1.4 Bln in Additional Licensed Target Fees and Milestone Payments

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Inc: Sangamo to Receive an $18 Mln Upfront License Fee

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Business Wire
·
04 Apr

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5

MT Newswires Live
·
19 Mar

Sangamo Therapeutics Price Target Maintained With a $2.00/Share by RBC Capital

Dow Jones
·
18 Mar